Medicine overview
Indications of Gadoscan
Gadoscan is a gadolinium-based contrast agent (GBCA) indicated for intravenous use in magnetic resonance imaging (MRI) to provide contrast enhancement that aids visualization of lesions and structures with abnormal vascularity or blood-brain-barrier disruption.
Established / FDA-approved indications
- Central nervous system (CNS) imaging: Contrast enhancement during cranial and spinal MRI in adult and pediatric patients (including term neonates) to visualize lesions with abnormal vascularity or blood-brain-barrier disruption.
- Extracranial/extraspinal (body) imaging: Contrast enhancement during MRI of the head and neck and body (including but not limited to the abdomen, pelvis, breast, and musculoskeletal soft tissue) in adults and pediatric patients 2 years of age and older, to visualize lesions with abnormal vascularity.
Guideline-supported / commonly performed uses
- Contrast-enhanced MR angiography (MRA) to assess vascular anatomy and patency, an established but sometimes off-label application depending on the specific vascular bed.
Note: Gadoscan is a diagnostic imaging agent, not a therapeutic drug — it has no treatment indication and is used solely to improve diagnostic image quality.
Composition
Each mL of Gadodiamide injection contains 287 mg of Gadodiamide (equivalent to a 0.5 mmol/mL gadolinium concentration), formulated with the excipient caldiamide sodium, added as a stabilizer to bind any free gadolinium ion, together with water for injection. The solution contains no antimicrobial preservative and is intended for single-patient, single-use intravenous administration.
Description
Gadoscan is a non-ionic, linear gadolinium-based contrast agent (GBCA) used to enhance the diagnostic quality of magnetic resonance imaging (MRI) studies. It is a paramagnetic chelate in which the metal gadolinium is bound to a diamide ligand, which reduces the toxicity of the free gadolinium ion while retaining its contrast-enhancing magnetic properties.
Gadoscan is administered only by, or under the supervision of, a physician or trained radiology personnel with resuscitation equipment immediately available; it is not a self-administered medication.
Therapeutic Class
Diagnostic Radiocontrast Agent — Gadolinium-based Contrast Agent (GBCA), non-ionic linear class; Gadoscan functions as a paramagnetic MRI contrast medium.
Pharmacology
Mechanism
Gadodiamide contains the paramagnetic gadolinium (Gd3+) ion, which shortens the T1 (and to a lesser extent T2/T2*) relaxation times of nearby water protons. This shortening increases signal intensity on T1-weighted MRI sequences, enhancing the visibility of tissues, lesions, and vasculature where the agent accumulates or where the blood-brain barrier is disrupted.
Pharmacokinetics
- Distribution: Gadodiamide rapidly distributes into the extracellular fluid compartment and does not cross an intact blood-brain barrier.
- Metabolism: Gadodiamide is not metabolized.
- Elimination: Gadodiamide is excreted essentially unchanged by the kidneys via glomerular filtration; elimination half-life is approximately 77 minutes in patients with normal renal function, and prolonged substantially in renal impairment.
Dosage & Administration of Gadoscan
Dosage of Gadoscan is calculated by body weight and administered as a single intravenous bolus injection; see the Dosage and Administration sections for indication-specific amounts and injection technique.
| Indication | Population | Recommended Dose |
|---|---|---|
| CNS (brain/spine) MRI | Adults | 0.1 mmol/kg (0.2 mL/kg) IV bolus of Gadoscan; a repeat dose immediately following the first may be used if clinically needed |
| CNS MRI | Pediatric (including term neonates) | 0.1 mmol/kg (0.2 mL/kg) IV bolus of Gadoscan |
| Body/extracranial MRI | Adults | 0.1 mmol/kg (0.2 mL/kg) IV bolus of Gadoscan |
| Body/extracranial MRI | Pediatric ≥ 2 years | 0.1 mmol/kg (0.2 mL/kg) IV bolus of Gadoscan |
Use the lowest dose of Gadoscan necessary to obtain adequate imaging, particularly in patients with reduced renal function (see Precautions and Warnings).
Administration of Gadoscan
Gadoscan is administered as an intravenous bolus injection, typically over 1–2 minutes or per MRI protocol, followed by a saline flush to ensure complete delivery of the dose. It must be visually inspected for particulate matter and discoloration before use, and any unused portion of a single-use vial of Gadoscan should be discarded. Administration should occur immediately before the imaging sequence, by a physician or trained personnel in a setting equipped with resuscitation equipment and staff trained to manage hypersensitivity reactions.
Interaction of Gadoscan
No clinically significant pharmacodynamic or pharmacokinetic drug-drug interactions have been well established for Gadoscan.
Notable interaction (laboratory, not pharmacologic)
Gadoscan can interfere with certain colorimetric laboratory methods, such as some serum calcium assays, producing a spurious, transient decrease in the measured calcium level that does not reflect a true drop in calcium. Clinicians should be aware of this artifact after recent Gadoscan administration to avoid unnecessary treatment for apparent hypocalcemia; if true hypocalcemia is suspected, confirm with an alternative assay method.
Contraindications
Gadodiamide is contraindicated in patients with a history of a prior severe hypersensitivity (including anaphylactic) reaction to Gadodiamide or its components.
No other absolute contraindication is established for Gadodiamide; severe renal impairment is a major precaution (a risk factor for nephrogenic systemic fibrosis) requiring careful risk-benefit assessment rather than an absolute prohibition — see Precautions and Warnings.
Side Effects of Gadoscan
| Frequency | Effects |
|---|---|
| Common | Headache, nausea, injection-site coldness/pain, dizziness, transient taste disturbance, sensation of warmth or flushing |
| Less common | Vomiting, paresthesia, pruritus, rash, hypotension |
| Serious (rare) | Anaphylactoid/hypersensitivity reactions (bronchospasm, facial/laryngeal edema, severe hypotension, cardiac arrest), nephrogenic systemic fibrosis in at-risk patients with severe renal impairment |
Seek urgent medical attention for any signs of a severe reaction (difficulty breathing, swelling of the face or throat, severe rash, chest pain) after Gadoscan administration.
Pregnancy & Lactation
Pregnancy
Gadoscan crosses the placenta, and animal reproduction studies have shown adverse fetal effects at repeated high doses. Gadoscan should be used during pregnancy only if the imaging information is essential and cannot be obtained without contrast or delayed until after delivery; use only if the potential diagnostic benefit justifies the potential risk to the fetus, and only on a physician's advice.
Lactation
Only a very small amount of Gadoscan is excreted into breast milk and absorbed by the infant. Many current guidelines consider continued breastfeeding after Gadoscan administration acceptable without interruption; a mother who wishes to be cautious may discuss temporary interruption with her physician on an individual basis.
Precautions & Warnings
Boxed Warning: Nephrogenic Systemic Fibrosis (NSF)
Gadolinium-based contrast agents, including Gadoscan, increase the risk of NSF in patients with impaired elimination of the drug, including those with acute kidney injury or chronic, severe kidney disease (eGFR less than 30 mL/min/1.73m²). Before administering Gadoscan, screen at-risk patients for renal dysfunction, use the lowest dose necessary for adequate imaging, and avoid repeated or higher-than-recommended doses, especially in patients with reduced renal function.
Other precautions
- Hypersensitivity reactions: Mild to severe, including fatal, anaphylactoid reactions can occur with Gadoscan, even without prior exposure; patients with a history of asthma or drug/contrast allergies are at higher risk. Resuscitation equipment and trained personnel must be available whenever Gadoscan is given.
- Gadolinium retention: Trace amounts of gadolinium from Gadoscan and other GBCAs can be retained in the brain and other body tissues for months to years, particularly with repeated administration; the clinical significance of retention is not established, but the minimum number of doses needed for diagnosis should be used.
- Not for intrathecal use: Gadoscan is approved for intravenous administration only and must not be given by the intrathecal route.
- Extravasation: Gadoscan may cause local irritation if it leaks outside the vein; monitor the injection site.
Overdose Effects of Gadoscan
There is limited clinical experience with overdose of Gadoscan. In the event of a suspected overdose, seek immediate medical attention or contact a poison control center or emergency services. Management is supportive, with monitoring of renal function and vital signs; Gadoscan is dialyzable, and hemodialysis may be used to help remove it from the body in patients with significant renal impairment, under medical supervision. Do not attempt home treatment for a suspected Gadoscan overdose.
Storage Conditions
Store Gadoscan at room temperature (below 30°C), protected from light. Do not freeze. Keep out of reach of children. Discard any unused portion; the vial or prefilled syringe is for single use only and contains no preservative.
Use In Special Populations
Renal impairment
Assess renal function before administering Gadoscan in patients with known kidney disease, a prior kidney transplant, or age over 60; see Precautions and Warnings for NSF risk.
Hepatic impairment
No specific dose adjustment of Gadoscan is established; use with caution due to potential for slower elimination if renal function is also affected, such as in hepatorenal syndrome.
Elderly
No specific age-related dose adjustment of Gadoscan is required beyond weight-based dosing, but elderly patients more commonly have reduced renal function, so renal assessment is advised.
Pediatric
See Pediatric Uses for age-specific approved indications and dosing of Gadoscan.
Duration Of Treatment
Gadoscan is administered as a single-dose diagnostic imaging agent rather than a course of treatment. It is given once, immediately before or during the MRI examination; a second dose may occasionally be used within the same imaging session for CNS studies if clinically indicated, at the treating physician's discretion. Repeat Gadoscan administration on separate occasions is determined by clinical and diagnostic need, not a fixed treatment duration.
Drug Classes
Gadolinium-based Contrast Agents (GBCAs); Paramagnetic MRI Contrast Media; Diagnostic Radiocontrast Agents; Non-ionic Linear Gadolinium Chelates — Gadodiamide belongs to this class.
Mode Of Action
Gadodiamide works by shortening the T1 relaxation time of water protons in tissues where it distributes, which increases signal intensity on T1-weighted MRI images. This paramagnetic effect makes lesions with increased vascularity, abnormal capillary permeability, or blood-brain-barrier disruption appear brighter and more clearly defined relative to surrounding normal tissue, improving diagnostic image contrast.
Pregnancy
C
Pediatric Uses
Gadoscan is approved for CNS (brain and spine) MRI contrast enhancement in pediatric patients of all ages, including term neonates, at a dose of 0.1 mmol/kg. For extracranial/body MRI, Gadoscan is approved in pediatric patients 2 years of age and older at the same weight-based dose; safety and efficacy of Gadoscan for body imaging in children younger than 2 years have not been established. As in adults, renal function and NSF risk factors should be considered before use of Gadoscan in any pediatric patient (see Precautions and Warnings).
Frequently Asked Questions
Q: What is Gadoscan 287 mg/ml IV Injection used for?
A: Gadoscan 287 mg/ml IV Injection is not a treatment; it is a gadolinium-based contrast agent injected before or during an MRI scan to make certain tissues, lesions, and blood vessels show up more clearly, helping doctors diagnose conditions of the brain, spine, and body.
Q: Is Gadoscan 287 mg/ml IV Injection safe for people with kidney problems?
A: Gadoscan 287 mg/ml IV Injection carries a boxed warning: in patients with severe kidney impairment or acute kidney injury, it can rarely cause a serious condition called nephrogenic systemic fibrosis (NSF). Anyone with known kidney disease should have their kidney function checked before receiving Gadoscan 287 mg/ml IV Injection, and doctors use the lowest effective dose and avoid repeated doses in this group.
Q: Can Gadoscan 287 mg/ml IV Injection be used during pregnancy or breastfeeding?
A: Gadoscan 287 mg/ml IV Injection should be used during pregnancy only if the scan information is essential and cannot wait until after delivery or be obtained without contrast, since it crosses the placenta. Only a tiny amount of Gadoscan 287 mg/ml IV Injection passes into breast milk, and many guidelines consider it acceptable to continue breastfeeding as normal after Gadoscan 287 mg/ml IV Injection, though you should confirm with your doctor.
Q: What are the common side effects of Gadoscan 287 mg/ml IV Injection?
A: Most people tolerate Gadoscan 287 mg/ml IV Injection well. The most common effects are mild, including headache, nausea, a cold or briefly painful sensation at the injection site, dizziness, or a temporary odd taste. Serious allergic reactions to Gadoscan 287 mg/ml IV Injection are rare but require immediate medical attention if they occur.
Q: Who should not receive Gadoscan 287 mg/ml IV Injection?
A: Gadoscan 287 mg/ml IV Injection should not be given to anyone who has had a previous severe allergic (anaphylactic) reaction to Gadoscan 287 mg/ml IV Injection. It also requires caution and careful risk assessment in patients with severe kidney impairment because of the risk of nephrogenic systemic fibrosis.
Q: Is Gadoscan 287 mg/ml IV Injection given as a pill?
A: No. Gadoscan 287 mg/ml IV Injection is only given as an intravenous injection by a physician or trained radiology staff immediately before or during an MRI scan; it is never taken orally or self-administered at home.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
